Weleader Biomedical Co (ROCO:7713) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7713 Weleader Biomedical Co Ltd ROCO:7713
66 GF Score
Price NT$71.10
GF Value NT$74.60
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Weleader Biomedical Co Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

ROCO:7713
66GF Score
Weleader Biomedical Co Ltd ROCO:7713
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Weleader Biomedical Co (ROCO:7713) Overvalued in 2026?

Based on GuruFocus' analysis, Weleader Biomedical Co stock appears to be undervalued. The current stock price of NT$71.10 is trading 4.7% below its estimated GF Value™ of NT$74.60. GuruFocus considers Weleader Biomedical Co to be Fairly Valued.

Key valuation signals for ROCO:7713:

  • Interest Received:
  • GF Value™: NT$74.60 vs. price of NT$71.10 (4.7% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the ROCO:7713 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Weleader Biomedical Co Business Description

Address No. 80, Minzu 1st Road, 19th Floor - 1 & 2, Sanmin District, Kaohsiung, TWN
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
66GF Score

Get the complete analysis for ROCO:7713

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$71.10
Price
NT$74.60
GF Value